Well I am not popular here, but it has not been my
Post# of 148115
I suggest we , as shareholders, ask CYDY to publish the full RTF and CRC from the FDA so we as owners of the company can make our own individual decisions. The documents are not subject NDA. It is entirely up to the sponsor how much to make public.
There has been a push by SEC and FDA since 2010 for full transparency, even citing mistrust that hiding the contents from stakeholders, the general public and other bio-tech companies who could benefit going forward from avoiding the same mistakes in their failure.
This is an article that demonstrates how often companies were honest in communicating the contents of the letter to the stakeholders:
https://jamanetwork.com/journals/jamainternal...le/2775955